Oxford Biomedica plc (OXB) Q4 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Oxford Biomedica Plc.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.128 -- 00:00:06.168 So good afternoon to everyone here in London and also good morning 00:00:06.168 -- 00:00:10.476 to those who are joining us from... 00:00:10.493 -- 00:00:15.741 Thank you for attending this call today, our analyst briefing 00:00:15.741 -- 00:00:17.904 for our 24 00:00:17.904 -- 00:00:23.091 preliminary results. It's great to see so many people here in the room, 00:00:23.091 -- 00:00:26.336 known faces. Thank you for joining. 00:00:26.336 -- 00:00:29.440 But we have also a few people joining virtually. 00:00:29.440 -- 00:00:34.688 So hello to everyone again. Presenting with me today, we have our Chief 00:00:34.688 -- 00:00:39.494 Financial Officer, Dr. Lucy Crabtree, 00:00:39.494 -- 00:00:42.699 who joined us in September 00:00:42.699 -- 00:00:47.767 last year and has already made a significant impact during this short 00:00:47.767 -- 00:00:49.249 period. 00:00:49.249 -- 00:00:52.855 I'm also pleased to welcome our Chief Business Officer, Dr. 00:00:52.855 -- 00:00:54.838 Sébastien Ribaud. 00:00:54.838 -- 00:00:59.906 You are known, I believe, well here and a lot of you are familiar 00:00:59.906 -- 00:01:02.147 with him. 00:01:03.211 -- 00:01:05.992 So disclaimer. 00:01:07.217 -- 00:01:11.463 Before we dive in, let's start with our agenda for today. 00:01:11.463 -- 00:01:16.991 As you can see, we will start with an overview of the key achievements across the business, 00:01:16.991 -- 00:01:22.298 highlighting what sets up OXP apart from our peers and how 00:01:22.298 -- 00:01:27.546 our differentiated pure play CDMO strategy and cell and gene therapy continues to drive 00:01:27.546 -- 00:01:32.693 our success. I will then hand over to Sébastien to provide us an 00:01:32.693 -- 00:01:37.900 update on the strong momentum we are seeing ...